Vertex Pharmaceuticals is strengthening its position in rare diseases with its $10 billion acquisition of Crinetics Pharmaceuticals. The deal adds Crinetics’ commercial and late-stage endocrinology assets, including treatments for acromegaly and congenital adrenal hyperplasia, while expanding Vertex’s pipeline beyond cystic fibrosis. The acquisition reflects the continued momentum in life sciences M&A as companies invest in innovative therapies, diversify their portfolios, and drive long-term growth.
Click here to read the entire article.
